Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Healing and recovery peptides are among the most actively studied compounds in regenerative medicine. From tendon and ligament repair to gut healing and wound recovery, peptides like BPC-157, TB-500, and GHK-Cu target tissue repair through distinct biological mechanisms. This guide covers five of the most researched healing peptides, their mechanisms of action, research dosing protocols, and what the preclinical and clinical data actually shows — without hype or medical advice.
| Peptide | Primary Target | Typical Research Dose | Status |
|---|---|---|---|
| BPC-157 | Tendon, ligament, muscle, gut repair | 250–500 mcg, 1–2x daily | Category 1 |
| TB-500 | Wound healing, cell migration, inflammation | 2–5 mg, 2x/week (loading) | Category 1 |
| GHK-Cu | Skin repair, collagen synthesis, wound healing | 200–600 mcg (SubQ); topical | Category 1 |
| KPV | Anti-inflammatory, gut healing, skin | 200–500 mcg (SubQ); 500 mcg–1 mg (oral) | Category 1 |
| Thymosin Beta-4 | Full-length protein; cardiac & corneal repair | 2–5 mg, 2x/week | Category 1 |
Also known as: Body Protection Compound-157, Bepecin
BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a protective protein found in human gastric juice. It is one of the most widely studied peptides in regenerative medicine, with extensive preclinical evidence for tissue healing across tendons, ligaments, muscles, and the gastrointestinal tract.
BPC-157 upregulates growth factor expression including VEGF (vascular endothelial growth factor), EGF (epidermal growth factor), and the FAK-paxillin pathway, promoting angiogenesis and tissue granulation. It also modulates nitric oxide synthesis and interacts with the dopaminergic system to exert cytoprotective effects.
SubQ: 250–500 mcg, 1–2 times daily. Injection near the injury site is the most common approach. Oral dosing is used for GI-related applications. Cycles of 4–6 weeks on, 2 weeks off are typical in research protocols.
Extensive preclinical research in rodent models demonstrates accelerated healing of tendons, ligaments, muscles, and the gastrointestinal tract. Studies show enhanced growth hormone receptor expression in tendon fibroblasts. BPC-157 remains one of the most studied peptides in regenerative medicine. Human clinical trials are limited but underway.
Contraindicated in individuals with active cancer or history of cancer due to its promotion of angiogenesis. Common side effects include nausea (especially oral), dizziness, injection site irritation, and headache. Category 1 regulatory status means availability through compounding pharmacies may be restricted.
Also known as: Thymosin Beta-4, TB4
TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring protein involved in cell migration, proliferation, and differentiation. It is studied for wound healing, tissue repair, and reduction of inflammation, and has been used extensively in equine veterinary medicine for injury recovery.
TB-500 promotes cell migration by upregulating actin, a cell-building protein critical for cell motility and structure. It reduces inflammation via downregulation of pro-inflammatory cytokines and supports new blood vessel formation at injury sites. The systemic nature of actin upregulation means TB-500 does not need to be injected near the injury site.
Loading phase: 2–5 mg subcutaneously, 2 times per week for 4–6 weeks. Maintenance: 2–5 mg once weekly. Can be injected anywhere subcutaneously — proximity to the injury site is not required due to its systemic mechanism.
Animal studies show significant benefits in wound healing, cardiac repair post-infarction, and corneal repair. Thymosin beta-4 research demonstrates promotion of dermal healing and cardiac tissue regeneration. Clinical trials in humans are limited, but the compound has a long track record in veterinary medicine.
Contraindicated in active cancer due to promotion of angiogenesis and cell migration. Side effects include headache, lethargy, injection site pain, and temporary head rush. TB-500 is dosed in milligrams (not micrograms like BPC-157), making it a higher-volume injection.
Also known as: Copper Peptide, GHK-Copper
GHK-Cu is a naturally occurring copper-binding tripeptide found in human plasma, saliva, and urine. It is studied extensively for its skin-remodeling, anti-aging, and wound-healing properties. GHK-Cu is unique among healing peptides because it is widely available in both injectable and topical cosmetic formulations.
GHK-Cu modulates gene expression involved in collagen synthesis, glycosaminoglycan production, and metalloproteinase regulation. The copper ion serves as a cofactor for lysyl oxidase and superoxide dismutase, supporting extracellular matrix remodeling and antioxidant defense. Genomic studies show it modulates expression of over 4,000 genes, many related to tissue repair.
SubQ: 200–600 mcg, 1–2 times daily. Topical: 1–2 mL serum application daily (products typically contain 1–3% GHK-Cu concentration). Topical application is the most common route for cosmetic and skin-healing applications.
Clinical studies confirm GHK-Cu stimulates collagen and elastin synthesis, promotes skin remodeling, and accelerates wound healing. Research demonstrates modulation of over 4,000 genes related to tissue repair. It has strong clinical evidence for topical skin applications and is widely used in cosmetic dermatology.
Contraindicated in Wilson’s disease or copper metabolism disorders. Side effects are generally mild: skin irritation or redness (topical), injection site discomfort, and mild inflammation at the treatment area. GHK-Cu is better suited for skin and cosmetic healing than deep tissue repair, where BPC-157 or TB-500 may be more appropriate.
Also known as: Lys-Pro-Val, Alpha-MSH (11-13)
KPV is a naturally occurring anti-inflammatory tripeptide derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH). It is studied for its potent anti-inflammatory effects in the gut and skin without the pigmentation effects of full alpha-MSH, making it a targeted anti-inflammatory agent.
KPV enters cells via the peptide transporter PepT1 and directly inhibits NF-kB activation and inflammatory cytokine production (IL-1β, IL-6, TNF-α). Unlike full-length alpha-MSH, KPV does not activate melanocortin receptors involved in pigmentation, which is why it reduces inflammation without causing skin darkening.
SubQ: 200–500 mcg, 1–2 times daily. Oral: 500 mcg–1 mg, 1–2 times daily (oral dosing targets gut inflammation directly). Topical application is used for localized skin conditions. Cycles of 4–8 weeks are typical.
Preclinical studies demonstrate significant anti-inflammatory effects in models of colitis, dermatitis, and systemic inflammation. Oral KPV has shown efficacy in reducing intestinal inflammation in IBD models. Research suggests particular promise for inflammatory bowel conditions and inflammatory skin disorders. Human clinical data is limited but emerging.
KPV is not a tissue-repair peptide in the same sense as BPC-157 or TB-500 — its primary value is in reducing inflammation, which supports the healing process. Contraindicated during active immunosuppressive therapy and in pregnancy. Side effects include injection site irritation, mild GI discomfort, headache, and fatigue.
Full-length protein — TB-500 is the active synthetic fragment
Thymosin beta-4 is a 43-amino-acid protein that is the natural, full-length version of the protein from which TB-500 is derived. It is the primary intracellular actin-sequestering protein in most mammalian cells and plays a critical role in cell migration, blood vessel formation, and tissue repair following injury.
Thymosin beta-4 sequesters G-actin monomers, regulating actin polymerization and cytoskeletal dynamics. This is essential for cell migration to injury sites. It also promotes angiogenesis, reduces oxidative damage, and decreases pro-inflammatory cytokines. TB-500 contains the active region of thymosin beta-4 responsible for most of these effects.
Dosing mirrors TB-500 protocols: 2–5 mg subcutaneously, 2 times per week during a loading phase of 4–6 weeks, followed by once-weekly maintenance. In practice, TB-500 (the synthetic fragment) is more commonly used in research settings.
Research on thymosin beta-4 demonstrates promotion of dermal healing, cardiac tissue regeneration after myocardial infarction, and corneal wound repair. It has been studied in clinical trials for chronic wound healing and cardiac recovery. The evidence base for the full-length protein overlaps significantly with TB-500.
Same contraindications as TB-500: active cancer due to angiogenesis and cell migration promotion. In research contexts, TB-500 (the synthetic fragment) is far more commonly used than full-length thymosin beta-4 due to availability and cost. The biological effects are considered largely equivalent.
These compounds target different aspects of the healing process. The best choice depends on the specific research context and tissue type involved.
Tendon, Ligament & Muscle Repair
BPC-157 + TB-500
BPC-157 is the most studied peptide for musculoskeletal tissue repair, with direct evidence for tendon and ligament healing. TB-500 complements it through systemic cell migration and inflammation reduction. Many research protocols combine both for this reason.
Gut Healing & Inflammation
BPC-157 + KPV
BPC-157 (especially oral formulations) has the strongest evidence for GI healing. KPV adds targeted anti-inflammatory action via NF-kB inhibition, making it particularly relevant for inflammatory bowel conditions. Oral administration of both provides direct GI exposure.
Skin Repair & Wound Healing
GHK-Cu + TB-500
GHK-Cu excels at skin-level tissue remodeling through collagen synthesis and gene expression modulation. TB-500 supports broader wound healing through cell migration. GHK-Cu topical formulations are widely available and well-tolerated.
General Recovery & Systemic Healing
TB-500 (systemic)
For general recovery support where a specific injury site is not the focus, TB-500’s systemic mechanism of actin upregulation makes it a versatile option. It can be injected anywhere subcutaneously and does not require proximity to the target tissue.
Based on the volume of preclinical research, BPC-157 and TB-500 are the most studied peptides for tissue healing. BPC-157 has the broadest evidence base for tendon, ligament, muscle, and gut repair. TB-500 shows particular promise for wound healing and cardiac repair. Many research protocols combine both compounds for synergistic effects. However, human clinical trial data remains limited for both.
Research protocols frequently combine BPC-157 and TB-500. The rationale is that they work through complementary mechanisms — BPC-157 upregulates growth factors and promotes angiogenesis, while TB-500 promotes cell migration via actin upregulation. There are no published studies on the specific combination, but the distinct mechanisms suggest potential synergy. Consult a healthcare provider before combining any compounds.
Research protocols for healing peptides typically run 4–8 weeks. Some users of BPC-157 report subjective improvement within the first 1–2 weeks, though tissue remodeling is a process that takes weeks to months. TB-500 protocols often use a loading phase of 4–6 weeks followed by a maintenance period. Results vary significantly depending on the nature and severity of the injury.
BPC-157 and TB-500 are generally considered to have favorable safety profiles in preclinical studies. Common side effects are mild: injection site irritation, headache, and nausea. However, both peptides promote angiogenesis (new blood vessel formation) and cell migration, which is contraindicated in individuals with active cancer. Human clinical trial data is limited. Consult a licensed healthcare provider.
For BPC-157, subcutaneous injection near the injury site is the most common approach in research protocols, as it may provide higher local concentration at the target tissue. TB-500 can be injected anywhere subcutaneously because its mechanism involves systemic upregulation of actin. GHK-Cu can be applied topically for skin and localized tissue applications. Injection technique guidance should come from a qualified healthcare provider.
BPC-157 and GHK-Cu work through different mechanisms. BPC-157 upregulates multiple growth factors (VEGF, EGF, FAK-paxillin) and modulates nitric oxide to promote healing of tendons, ligaments, muscles, and gut tissue. GHK-Cu is a copper-binding tripeptide that modulates gene expression involved in collagen synthesis and extracellular matrix remodeling — it is particularly studied for skin repair and cosmetic applications. BPC-157 has a broader tissue-repair evidence base, while GHK-Cu excels in skin-specific applications.
BPC-157, TB-500, GHK-Cu, and KPV are Category 1 peptides under the FDA's compounding framework, which means they face additional regulatory scrutiny and may not be available through compounding pharmacies. They remain available as research chemicals. The regulatory landscape continues to evolve. Check our regulatory alerts page for the latest updates.
BPC-157 has the most extensive preclinical evidence for gastrointestinal healing. Studies demonstrate efficacy in models of inflammatory bowel disease, gastric ulcers, and NSAID-induced GI damage. Oral BPC-157 formulations provide direct exposure to the GI mucosa. KPV, an anti-inflammatory tripeptide, has also shown efficacy in reducing intestinal inflammation in preclinical IBD models. Both are being actively studied for gut health applications.
Use our free tools to compare prices, calculate reconstitution doses, and explore pre-built healing protocols.
This platform provides informational tools only, not medical advice. Consult a licensed provider.
This guide is for educational purposes only. It is not medical advice. Consult a licensed healthcare provider before using any peptide.
Disclosed Labs